Does BPC-157 promote angiogenesis?

Vascular effects are consistently reported in preclinical models, with VEGF-related signalling implicated. The mechanism behind it is not established.

Why would that explain effects in different tissues?

Repair in most tissues depends on blood supply, so one vascular mechanism could produce apparent activity across unrelated systems.

Is promoting angiogenesis desirable?

Not uniformly. It underlies tumour growth as well as tissue repair, which is why the field describes it carefully.

BPC-157 and Angiogenesis Research

The short answer

Vascular effects are among the most consistently reported findings, with Seiwerth and colleagues reviewing BPC-157 and blood vessels in Current Pharmaceutical Design in 2014. Angiogenesis is the most plausible common thread linking reported activity across otherwise unrelated tissues.

Key facts

Key review: Seiwerth, Curr Pharm Des 2014 (PMID 23782145)
Reported involvement: VEGF-related signalling
Model systems: Predominantly rat
Why it matters: Repair in most tissues requires vasculature
Receptor: None identified
Human data: Limited

Why angiogenesis could be the unifying thread

BPC-157 is reported active in gut, tendon, ligament, muscle and eye. Those tissues have little in common except that repair in all of them requires blood supply. If a compound affects vessel formation, effects across unrelated tissues become less surprising: one mechanism producing many apparent activities rather than many separate mechanisms.

What the literature reports

Seiwerth and colleagues reviewed the vascular findings in 2014. Reported involvement includes VEGF-related signalling, which is the principal pathway driving new vessel formation. Effects on vessel behaviour in injury models recur across the Zagreb group's output in different tissue systems.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £15.99

The mechanistic gap that remains

Reporting that a compound affects angiogenesis is not the same as explaining how. Without an identified receptor there is no molecular starting point, so the angiogenic finding is itself a description rather than a mechanism. It moves the question from why does this work in five tissues to how does it affect vessels, which is progress but not resolution.

The caution angiogenesis always warrants

Promoting vessel growth is not uniformly beneficial. Angiogenesis is central to tumour growth as well as to tissue repair, which is why the therapeutic angiogenesis field has proceeded carefully. A compound reported to promote it deserves that same care in description, and this library reports findings rather than characterising them as benefits.

Where the evidence sits

Predominantly rat models from one research group. The currently recruiting Phase 2 trial in hamstring muscle strain is relevant here. Muscle repair depends on vascular supply, so a positive result would be consistent with the angiogenic hypothesis, though a clinical endpoint does not identify a mechanism.

Frequently asked questions

Does BPC-157 promote angiogenesis?: Vascular effects are consistently reported in preclinical models, with VEGF-related signalling implicated. The mechanism behind it is not established.
Why would that explain effects in different tissues?: Repair in most tissues depends on blood supply, so one vascular mechanism could produce apparent activity across unrelated systems.
Is promoting angiogenesis desirable?: Not uniformly. It underlies tumour growth as well as tissue repair, which is why the field describes it carefully.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it. Different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

BPC-157 and Blood Vessels